Resistance to aspirin: Prevalence, mechanisms of action and association with thromboembolic events. A narrative review;Resistencia a la aspirina: prevalencia, mecanismos de acción y asociación con eventos tromboembólicos. Revisión narrativa

Farmacia Hospitalaria

Volumn 34, Issue 1, 2010, Pages 32-43

  Canivano Petrenas L ^a   Garcia Yubero C ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Acetylsalicylic acid; Cardiovascular disease; Drug resistance; Epidemiology; Mechanism of action; Review; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MORTALITY; PREVALENCE; SHORT SURVEY; STROKE; THROMBOEMBOLISM;

ASPIRIN; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PREVALENCE; THROMBOEMBOLISM;

EID: 75849116036     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farma.2009.08.002     Document Type: Short Survey

References (95)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-6.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-6
3. Vane J.R., Bakhle Y.S., and Botting M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120 Health & Medical Complete. p.97
4. Gum P.A., Kottke-Marchant K., Poggio E., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
5. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 126 (2004) 234S-264S
6. Pamuckcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis 23 (2007) 213-222
7. Michelson A.D. Methods for the measurement of platelet function. Am J Cardiol 103 (2009) 20A-26A
8. Harrison P., Segal H., Blasbery K., Furtado C.H., Silver L., and Rothwell P.M. Screening for aspirin responsiveness after transient isquemic attack and stroke: Comparison of 2 point-of-care platelet function test with optical aggregometry. Stroke 36 (2005) 1001-1005
9. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.J., Ushiwata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
10. Berrouschot J., Schwetlick B., Von Twickel G., Fisher C., Uhlemann H., Siegemund T., et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113 (2006) 31-35
11. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
12. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
13. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
14. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., et al. Aspirin response and failure in cerebral infarction. Stroke 24 (1993) 345-350
15. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
16. Macchi L., Petit E., Brizard A., Gil R., and Neau P. Aspirin resistance in vitro and hypertension in stroke patients. J Thromb Haemost 1 (2003) 1710-1713
17. Tarján J., Salamon A., Jáger R., Poór F., Barczi V., Dinnyés J., et al. The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv Hetil 140 (1999) 2339-2343 [Artículo en húngaro] Resumen
18. Coma-Canella I., Velasco A., and Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101 (2005) 71-76
19. Christiaens L., Macchi L., Herpin D., Coisne D., Duplantier C., Allal J., et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 108 (2003) 115-119
20. Dussaillant G., Zapata M., Fardella P., Conte G., and Cuneo M.V. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Rev Med Chile 133 (2005) 409-417
21. Friend M., Vucenik I., and Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326 (2003) 82-83
22. Gum P.A., Kottke-Marchant K., Poggio E., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
23. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
24. Kuliczkowski W., Halawa B., Korolko B., and Mazurek W. Aspirin resistance in ischaemic heart disease. Kardiol Pol 62 (2005) 14-25 [Artículo en polaco]. Resumen
25. Lee P.-Y., Chen W.-H., Ng W., Cheng X., Kwok J Y.-Y., Tse H.-F., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
26. A1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibα) polymorphisms. J Am Coll Cardiol 42 (2003) 1115-1119
27. Pamucku B., Oflaz H., Oncul A., Umman B., Mercanoglu F., Ozcan M., et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 22 (2006) 103-110
28. Wang J.C., Aucoin-Barry D., Manuelian D., Monbouquette R., Reisman M., Gray W., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92 (2003) 1492-1494
29. Buchanan M.R., Schwartz L., Bourassa M., Brister S.J., Peniston C.M., and BRAT investigators. Results of the BRAT study: A pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 16 (2000) 1385-1390
30. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2003) 37-42
31. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., and De Franco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95 (2005) 973-975
32. Golanski J., Chlopicki S., Golanski R., Gresner P., Iwaszkiewicz A., and Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient. Ther Drug Monit 27 (2005) 484-490
33. Yilmaz M.B., Balbay Y., Caldir V., Ayaz S., Guray Y., Guray U., et al. Late saphenous vein graft occlusion in patients with coronary bypass: Possible role of aspirin resistance. Thromb Res 115 (2005) 25-29
34. Chen W.-H., Lee P.-Y., Ng W., Tse H.-F., and Lau C.-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percuatneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
35. Chen W.-H., Lee P.-Y., Ng W., Kwok Y.-T., Cheng X., Lee S W.-L., et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 96 (2005) 760-763
36. Tantry U.S., Bliden K.P., and Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005) 1705-1709
37. Roller R.E., Dorr A., Ulrich S., and Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 13 (2002) 277-281
38. Sane D.C., McKee S.A., Malinin A.I., and Serebruany V.L. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 90 (2002) 893-895
39. Christiaens L., Ragot S., Mergy J., Allal J., and Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: A prospective study. Blood Coagul Fibrinolysis 19 (2008) 235-239
40. Stejskal D., Václavík J., Lacnák B., and Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 17 (2006) 349-354
41. Hovens M.M.C., Snoep J.D., Eikenboom J.C.J., Van der Bom J.G., Mertens B.J.A., and Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am Heart J 153 (2007) 175-181
42. Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., and De Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. Thromb Haesmost 99 (2008) 14-26
43. Pamucku B., Oflaz H., Onur I., Oncul A., Ozcan M., Umman B., et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: A prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 18 (2007) 187-192
44. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of miocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
45. Poston R.S., Gu J., Brown J.M., Gammie J.S., White C., Nie L., et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 131 (2006) 122-130
46. Mueller M.R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
47. Snoep J.D., Hovens M.M.C., Eikenboom J.C.J., Van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 167 (2007) 1593-1599
48. Krasopoulos G., Brister S.J., Beattie W.S., Elliot R.F., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 336 (2008) 195-198
49. Reny J.L., De Moerloose P., Dauzat M., and Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 6 (2008) 444-450
50. Crescente M., Di Castelnuovo A., Iacovello L., De Gaetano G., and Cerletti C.H. PFA-110 closure to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 99 (2008) 1129-1131
51. Feher G., Koltai K., Papp E., Alkonyi B., Solyom A., Kenyeres P., et al. Aspirin resistance: Possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 23 (2006) 559-567
52. Catella-Lawson F., Reilly M., Kapoor S.C., Cucchiara A.J., De Marco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 345 (2001) 1809-1817
53. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
54. Iñarrea P., Esteva F., Cornudella R., and Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 35 (2000) 242-246
55. Halushka M.K., and Halushka P.V. Why are some individuals resistant to the cardioprotective effects of aspirin?: Could it be thromboxane A2?. Circulation 105 (2002) 1620-1622
56. Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., and Schör K. Cyclooxigenase-2 in human platelets as a possible factor in aspirin resistance. The Lancet 353 (1999) 9156
57. Cipollone F., Patrignani P., Greco A., Panara M.R., Padovano R., Cuccurullo F., et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96 (1997) 1109-1116
58. Patrono C., Bachmann F., Baigent C., Bode C.h., De Caterina R., Charbonnier B., et al. Documento de consenso de expertos sobre el uso de agentes antiplaquetarios. Rev Esp Cardiol 57 (2004) 963-980
59. Zimmermann N., Wenk A., Kim U., Kienzle P., Weber A.-A., Gams E., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108 (2003) 542-547
60. Zimmermann N., Kienzle P., Weber A.-A., Winter J., Gams E., Schör K., et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 121 (2001) 982-984
61. Halushka M.K., Walker L.P., and Halushka P.V. Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 73 (2003) 122-130
62. A2 polymorphism and efficacy of aspirin. The Lancet 351 (1998) 1253
63. Michelson A.D., Furman M.I., Goldschmidt-Clermont P., Mascelli M.A., Hendrix C., Coleman L., et al. Platelet GP IIIa PI(A) polymorphisms display different sensitivities to agonists. Circulation 101 (2000) 1013-1018
64. Undas A., Sanak M., Musial J., and Szczeklik A. Platelet glycoprotein iiia polymorphism, aspirin, and thrombin generation. The Lancet 353 (1999) 982-983
65. Weiss E.J., Bray P.F., Tayback M., Schulman S., Kickler T., Becker L.C., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334 (1996) 1090-1094
66. Bray P.F. Platelet glycoprotein polymorphisms as a risk factors for thrombosis. Curr Opin Hematol 7 (2000) 284-289
67. A polymorphism and effects of aspirin on thrombin generation. Circulation 103 (2001) E33-E34
68. TM closure time: Pivotal role of plasma Von Willebrand factor. Br J Hematol 124 (2004) 80-85
69. Borna C., Lazarowski E., Van Heusden C., Öhlin H., and Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thrombosis Journal 3 (2005) 10
70. Kawasaki T., Ozeki Y., Igawa T., and Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31 (2000) 591-595
71. Cipollone F., Ciabattoni G., Patrignani P., Pasquale M., Di Gregorio D., Bucciarelli T., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 (2000) 1007-1013
72. 2-isoprostanes) in smokers. N Engl J Med 332 (1995) 1198-1203
73. Reilly M., Delanty N., Lawson J.A., and FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94 (1996) 19-25
74. Davis J.W., Hartman C.R., Lewis Jr. H.D., Shelton L., Eigenberg D.A., Hassanein K.M., et al. Cigarette smoking: Induced enhancement of platelet function: Lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 105 (1985) 479-483
75. Hung J., Lam J., Lacoste L., and Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92 (1995) 2432-2436
76. Weber A.A., Liesener S., Schanz A., Hohlfeld T., and Schrör K. Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin resistance. Platelets 11 (2000) 177-182
77. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Luzak B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): Its relation to metabolic control. Thromb Res 113 (2004) 101-113
78. Fateh-Moghadam S., Plöckinger U., Cabeza N., Htun P., Reuter T., Ersel S., et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42 (2005) 99-103
79. Mori T.A., Vandongen R., Douglas A.J., McCulloch R.K., and Burke V. Differential effect of aspirin on platelet aggregation in IDDM. Diabetes 41 (1992) 261-266
80. Tamminen M., Lassila R., Westerbacka J., Vehkavaara S., and Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 27 (2003) 907-911
81. Modica A., Karlsson F., and Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 5 (2007) 507-511
82. Larsson P.T., Wallén N.H., and Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 89 (1994) 1951-1957
83. Pamukcu B., Oflaz H., Acar R.D., Umman S., Koylan N., Umman B., et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: Exercise induces aspirin platelet activation. Journal of Thrombosis and Thrombolysis 20 (2005) 17-22
84. Cotter G., Shemesh E., Zehavi M., Dinur I., Rudnick A., Milo O., et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin?. Am Heart J 147 (2004) 293-300
85. Tohgi H., Konno S., Tamura K., Kimura B., and Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23 (1992) 1400-1403
86. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
87. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358 (2001) 527-533
88. Sabatine M.S., Cannon C.P., Gibson C.M., López-Sendón J.L., Montalescot G., Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
89. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.H.M. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
90. Matetzky S., Shenkman B., Guetta V., Schechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
91. Müller I., Besta F., Schulz C.H., Massberg S., Schönig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheluded for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
92. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., De Lao T., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. Am Coll Cardiol 47 (2006) 27-33
93. Lordkipanidzé M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., and Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708
94. Frelinger A.L., Li Y., Linden M.D., Tarnow I., Barnard M.R., Fox M.L., et al. Aspirin 'resistance': Role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 6 (2008) 2035-2044
95. Pulcinelli F.M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P.P., and Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43 (2004) 979-984